? 2018 Sustainable Value Report published
? Diverse, long-term commitments to sustainability
? Ongoing activities carefully aligned with corporate values and key international targets
Osaka, Japan, October 18, 2018 --- Takeda Pharmaceutical Company Limited, (“Takeda”) (TSE:4502) today announced the publication of its 2018 Sustainable Value Report, which details the company's programs dedicated to sustainable value creation, and their achievements to date.
The report showcases results achieved through Corporate Social Responsibility (CSR) activities, such as Takeda’s Access to Medicines (AtM) Strategy for patients with the highest unmet medical needs, and the Global CSR Program, which prioritizes long-term commitments to disease prevention, capacity-building, and access to healthcare in developing and emerging countries. By working together with the global community, Takeda's CSR activities closely align with the Sustainable Development Goals (SDGs) and global standards set by international frameworks, such as the United Nations Global Compact. Also featured are key materiality assessments including, for example, proactive CO2 reduction based on the Paris Agreement, employee health and safety, constant re-evaluation and training to ensure sustainable, world-class supply chains and compliance systems, and many others.
According to CEO Christophe Weber, “Takeda’s impact to date galvanizes us to reach for greater heights. Recognition of that impact by independent benchmarking humbles us, reminding us that we are truly a global community collectively striving for Better Health and a Brighter Future for patients everywhere.”
The digital version of Takeda's 2018 Sustainable Value Report is online at: <LINK>
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit http://www.asiamerlion.cn/newsroom/
+81 (0) 3-3278-2724